Lung Cancer Incidence and Mortality in a Nationwide 45-year Prospective Cohort of Persons with Opioid Use Disorder

Lung cancer remains the leading cause of cancer death for men and women around the world, a disease where the timing of discovery often dictates the outcome. When doctors find the disease early, while it is still small and contained, patients have a much higher chance of survival. However, when the cancer is found after it has spread to other parts of the body, treatment becomes far more difficult and the outlook is grim. A major factor in this tragedy is tobacco use, which is responsible for the vast majority of lung cancer cases. Because smoking is so common, public health officials have established specific rules for who should be screened for the disease using low-dose CT scans, a powerful imaging tool that can spot tumors before symptoms appear. These rules currently look at a person's age and how much they have smoked over their lifetime, measured in "pack-years," which is the number of packs smoked per day multiplied by the number of years smoked. Yet, there is a large group of people who face unique health challenges and high rates of smoking, yet who have not been closely studied regarding their lung cancer risk: individuals struggling with opioid use disorder.

For decades, a team of researchers has been tracking the long-term health of nearly ten thousand people in the United States who were receiving treatment for opioid use disorder. These individuals entered the study starting in the 1980s, filling out questionnaires about their lives, their drug use, and their smoking habits, and agreeing to have their health records followed indefinitely. The goal was to understand what happens to this population over time. In a recent analysis of this massive, forty-five-year dataset, the researchers turned their attention specifically to lung cancer. They wanted to know if people with opioid use disorder were developing this disease more often than the general public, if they were dying from it at higher rates, and whether the cancer was being caught early enough to save lives.

The findings reveal a stark reality. The researchers found that people with opioid use disorder are developing lung cancer at roughly twice the rate of the general population. They are also dying from it at more than double the expected rate. This elevated risk is not limited to a specific age or gender; it was observed across the board, though it was particularly pronounced among those who also had HIV infection, where the risk was even higher. The study also highlighted a troubling pattern in how the disease is discovered. In the general population, about twenty-eight percent of lung cancers are found at a localized stage, meaning they are confined to the lung. In this group of patients with opioid use disorder, that number was significantly lower, with nearly half of the cases already having spread to distant parts of the body by the time they were diagnosed. This late discovery explains much of the higher death rate, as advanced cancer is far harder to treat successfully.

A critical part of the study examined whether the current rules for lung cancer screening are working for this specific group. The standard guidelines suggest screening for people who are at least fifty years old and have a smoking history of at least twenty pack-years. The researchers looked closely at the patients in their study and found that a significant number of those who developed lung cancer did not meet these criteria. Many had smoked for fewer than twenty pack-years, yet they still developed the disease at rates far higher than non-smokers in the general population. This suggests that the current screening thresholds might be too strict for people with opioid use disorder, potentially missing those who are at high risk but fall just below the official cutoff. Furthermore, the average age at which these patients were diagnosed was fifty-nine, which is a decade younger than the average age of diagnosis for the general population. This indicates that the disease may be striking this group earlier than it does others.

The study also explored the role of smoking intensity. The researchers found a clear dose-response relationship: the more a person smoked, the higher their risk of developing and dying from lung cancer. However, even among those who smoked less, the risk remained significantly elevated compared to the general public. This points to the possibility that factors beyond just the amount of tobacco smoked—perhaps related to the biology of opioid use disorder or the specific patterns of drug use—might be contributing to the danger. Despite the high rates of smoking in this population, with nearly ninety percent of participants having smoked at some point, the study noted that smoking habits did not change much over time for those who were enrolled multiple times. This suggests that while these individuals are in treatment for their opioid use, they are not receiving enough support to quit smoking, a gap that leaves them vulnerable to lung cancer.

The researchers concluded that the current approach to lung cancer prevention and screening may be failing this high-risk group. They argue that the standard guidelines, which rely heavily on age and a strict count of smoking history, may not be sensitive enough to capture the true risk faced by people with opioid use disorder. The data suggests that lowering the age for screening or adjusting the smoking thresholds could help catch the disease earlier. More importantly, the study highlights a missed opportunity within drug treatment programs. Since these patients are already in contact with healthcare providers for their opioid treatment, these settings could be ideal places to integrate lung cancer education, smoking cessation support, and screening referrals. By bringing these services together, doctors and clinics could potentially save lives that are currently being lost to late-stage diagnoses. The study does not claim to have solved the problem or proven exactly why the risk is so high, but it provides a clear, data-driven map of the danger, urging a rethinking of how we protect one of the most vulnerable populations from a preventable and deadly disease.